A phase-I study showed good antitumor activity in HER-2 mutant NSCLC and objective response in 72.7% of the patients (n = 11; 95% confidence interval [CI], 39.0 to 94.0), but interstitial lung disease (ILD) emerged as a specific safety signal [76]. The gene discussed is ERBB2; the disease is interstitial lung disease.